Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-004920-67-NL
EUCTR2015-004920-67-NLActive, not recruitingPhase 1

Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma - CheckMate 511: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 511

Bristol-Myers Squibb International Corporation0 sites460 target enrollmentStarted: April 4, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
460
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •-Adult subjects (>=18 years) with histologically confirmed unresectable Stage III or Stage IV Melanoma as per AJCC staging system.
  • •-Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • •-No prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant or neoadjuvant melanoma therapy is permitted if it was completed at least 6 weeks prior to date of first dose, and all related adverse events have either returned to baseline or stabilized.
  • •-Measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) criteria
  • •-Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses. In order to be randomized, a subject must be classified as PD-L1 positive, PD-L1 negative, or PD-L1 indeterminate. If an insufficient amount of tumor tissue from an unresectable or metastatic site is available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue for performance of biomarker analyses.
  • •-Known BRAF V600 mutation status as determined by local institutional standard or subject to consent to BRAF V600 mutation testing per local institutional standards during the Screening Period, the results of which must be reported within 3 months of randomization. All BRAF statuses (BRAF wild-type or BRAF 600 mutation positive) are eligible.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 322
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 138

Exclusion Criteria

  • •- Active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if these have been treated and there is no evidence of progression via magnetic resonance imaging (MRI, except where contraindicated in which CT scan is acceptable) for at least 8 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. There must also be no requirement for high doses of systemic corticosteroids that could result in immunosuppression (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
  • •-Ocular melanoma
  • •-Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 18.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004920-67-ESBristol-Myers Squibb International Corporation385
Active, not recruiting
Phase 1
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004920-67-GBBristol-Myers Squibb International Corporation460
Active, not recruiting
Phase 1
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaSubjects with Previously Untreated, Unresectable or Metastatic MelanomaMedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004920-67-DKBristol-Myers Squibb International Corporation460
Recruiting
Phase 3
Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic MelanomaAdvanced (unresectable or metastatic) melanoma10040900
NL-OMON47433Bristol-Myers Squibb30
Active, not recruiting
Phase 1
A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
EUCTR2015-004920-67-DEBristol-Myers Squibb International Corporation460